Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination
Henoch Schönlein purpura (HSP) following vaccine administration has been described in case reports and in a small number of observational studies. We herein reported a case of HSP occurring in an otherwise healthy 37-year-old male after immunization with lyophilized purified vero cell rabies vaccine...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1486354 |
| _version_ | 1797677483190910976 |
|---|---|
| author | Zheng-Gang Zhu Yi Zheng Sha Lu Quan Hu Yuan Fang |
| author_facet | Zheng-Gang Zhu Yi Zheng Sha Lu Quan Hu Yuan Fang |
| author_sort | Zheng-Gang Zhu |
| collection | DOAJ |
| description | Henoch Schönlein purpura (HSP) following vaccine administration has been described in case reports and in a small number of observational studies. We herein reported a case of HSP occurring in an otherwise healthy 37-year-old male after immunization with lyophilized purified vero cell rabies vaccine (PVRV). After the anti-allergy therapy with hormone, the purpuric lesions gradually disappeared. After evaluating, another PVRV with different dose (0.5 ml), strains, excipient and without residues was chosen for the new anti-rabies immunization program, and the patient has had no recurrence of allergic symptoms. Although significant lower than the levels of normal 20–50 year population at day 21, the neutralizing antibody (RVNA) titers of this boy showed adequate protective antibody (3.23 vs 7.15 IU/ml). This case report emphasizes the importance that clinicians should be aware of HSP as a potential adverse event associated with PVRV vaccination. And adverse events (AEs) after immunization should be carefully treated, changing immunization program in time is necessary. While enrolling a new anti-rabies immunization program, the properties of different rabies vaccines taking with special emphasis on strains, excipient and residues is imperative before vaccination so that an appropriate immune program can be managed to be initiated. |
| first_indexed | 2024-03-11T22:45:47Z |
| format | Article |
| id | doaj.art-83b7aa8431514d7e8b28398b5fef1141 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:45:47Z |
| publishDate | 2018-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-83b7aa8431514d7e8b28398b5fef11412023-09-22T08:38:22ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2018-11-0114112666266810.1080/21645515.2018.14863541486354Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccinationZheng-Gang Zhu0Yi Zheng1Sha Lu2Quan Hu3Yuan Fang4Wuhan Center for Disease Prevention and ControlWuhan Institute of Dermatology and VenereologyWuhan Center for Disease Prevention and ControlWuhan Institute of Dermatology and VenereologyHuazhong University of Science and TechnologyHenoch Schönlein purpura (HSP) following vaccine administration has been described in case reports and in a small number of observational studies. We herein reported a case of HSP occurring in an otherwise healthy 37-year-old male after immunization with lyophilized purified vero cell rabies vaccine (PVRV). After the anti-allergy therapy with hormone, the purpuric lesions gradually disappeared. After evaluating, another PVRV with different dose (0.5 ml), strains, excipient and without residues was chosen for the new anti-rabies immunization program, and the patient has had no recurrence of allergic symptoms. Although significant lower than the levels of normal 20–50 year population at day 21, the neutralizing antibody (RVNA) titers of this boy showed adequate protective antibody (3.23 vs 7.15 IU/ml). This case report emphasizes the importance that clinicians should be aware of HSP as a potential adverse event associated with PVRV vaccination. And adverse events (AEs) after immunization should be carefully treated, changing immunization program in time is necessary. While enrolling a new anti-rabies immunization program, the properties of different rabies vaccines taking with special emphasis on strains, excipient and residues is imperative before vaccination so that an appropriate immune program can be managed to be initiated.http://dx.doi.org/10.1080/21645515.2018.1486354allergic reactionneutralizing antibody (rvna) titerpurified vero cell rabies vaccine (pvrv)rabies virus neutralizing antibody (rvna)henoch schönlein purpura (hsp) |
| spellingShingle | Zheng-Gang Zhu Yi Zheng Sha Lu Quan Hu Yuan Fang Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination Human Vaccines & Immunotherapeutics allergic reaction neutralizing antibody (rvna) titer purified vero cell rabies vaccine (pvrv) rabies virus neutralizing antibody (rvna) henoch schönlein purpura (hsp) |
| title | Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination |
| title_full | Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination |
| title_fullStr | Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination |
| title_full_unstemmed | Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination |
| title_short | Rabies post-exposure prophylaxis for a male with severe Henoch Schönlein purpura following rabies vaccination |
| title_sort | rabies post exposure prophylaxis for a male with severe henoch schonlein purpura following rabies vaccination |
| topic | allergic reaction neutralizing antibody (rvna) titer purified vero cell rabies vaccine (pvrv) rabies virus neutralizing antibody (rvna) henoch schönlein purpura (hsp) |
| url | http://dx.doi.org/10.1080/21645515.2018.1486354 |
| work_keys_str_mv | AT zhenggangzhu rabiespostexposureprophylaxisforamalewithseverehenochschonleinpurpurafollowingrabiesvaccination AT yizheng rabiespostexposureprophylaxisforamalewithseverehenochschonleinpurpurafollowingrabiesvaccination AT shalu rabiespostexposureprophylaxisforamalewithseverehenochschonleinpurpurafollowingrabiesvaccination AT quanhu rabiespostexposureprophylaxisforamalewithseverehenochschonleinpurpurafollowingrabiesvaccination AT yuanfang rabiespostexposureprophylaxisforamalewithseverehenochschonleinpurpurafollowingrabiesvaccination |